Annual Report 2025

MANAGEMENT DISCUSSION AND ANALYSIS 13 The United Laboratories International Holdings Limited Annual Report 2025 Anti-infection The main products include 聯邦他唑仙 ® (Piperacillin Sodium Tazobactam Sodium for Injection), 聯邦 ® 阿莫仙 ® (Amoxicillin Capsules/Granules), 強力阿莫仙 ® (Potassium Amoxicillin Clavulanate for Injection, Potassium Amoxicillin Clavulanate Tablets/Dry Suspensions), and 聯邦倍能安 ® (Imipenem Cestastatin Sodium for Injection), among others. During the year, the anti-infection products (for human use) recorded total sales of RMB1,814.0 million, representing a year-on-year increase of 0.9%. Other human-used finished products The main products include ophthalmic drugs, topical dermatological drugs, etc. During the year, other human-used finished products recorded total sales of RMB212.4 million, representing a year-on-year decrease of 28.9%. Health & Wellness The main products include the United Health & Beauty series of healthcare products, United Biophin series of skincare products, etc. The Health & Wellness Division of the Group has deployed five major product lines: general dietary supplements, healthcare food products, cross-border nutritional supplements, medical devices, medical and aesthetic skincare products, covering categories such as bone and joint nutrition, intestinal regulation, cardiovascular health, vision protection and immunity enhancement. At present, we have a matrix of e-commerce, live broadcasting and new retail online platforms represented by Tmall, JD.com, Tik Tok and WeChat Mall, and deepened our coverage of pharmacy chains and health vertical pipelines. During the year, the Health & Wellness segment recorded sales of RMB37.1 million, representing a year-on-year increase of 85.8%.